ACE and heart failure: For this reason, ARBs may be preferred over ACE-i in heart failure patients with a past medical history of myocardial infarction, as the former do not target the other isoform of the ATIIR, ATIIR2, which is instead selectively expressed under inflammatory conditions and mediates the inhibition of cell growth, protection against ischemia, and decreased extracellular matrix formation [145].